Compare ADMA Biologics Inc (ADMA) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Synopsys, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 35.4× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | SNPS | |
|---|---|---|
Market Cap | $2.22B | $78.68B |
Sector | Health | Technology |
52-Week High | $20.38 | $625.80 |
52-Week Low | $7.60 | $372.33 |
Enterprise Value | $2.29B | $87.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
